Welcome to our dedicated page for Verona Pharma plc news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma plc stock.
Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.
The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.
Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.
Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.
Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.
For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.
Verona Pharma (Nasdaq: VRNA) has appointed Matthew Casbon as Vice President of Sales, Marketing and Training, and Matthew Rysavy as Vice President of Market Access and Trade, both bringing around 25 years of experience in commercialization. These appointments coincide with the positive Phase 3 results from the ENHANCE-2 trial of ensifentrine for chronic obstructive pulmonary disease (COPD). The Company anticipates reporting results from the ENHANCE-1 trial by year-end, with plans to submit a New Drug Application to the FDA in early 2023 if positive results are obtained.
Verona Pharma plc (Nasdaq: VRNA) announced that its development partner, Nuance Pharma, received IND approval from the Center of Drug Evaluation to initiate Phase 1 and Phase 3 studies for ensifentrine, targeting COPD treatment in mainland China. This follows a $219 million agreement from 2021, which included a $25 million upfront payment and future milestone payments. The ENHANCE-2 trial showed significant improvements in lung function with ensifentrine, indicating promising potential in addressing COPD.
Verona Pharma (Nasdaq: VRNA) has successfully completed an upsized public offering, closing the sale of 14,260,000 American Depositary Shares (ADSs) at $10.50 each, netting approximately $150 million before expenses. This offering included the full exercise of an underwriters' option for an additional 1,860,000 ADSs. The funds raised will support the development of Verona's respiratory disease treatments. The offering was managed by Jefferies, Piper Sandler & Co., and Truist Securities.
Verona Pharma plc (Nasdaq: VRNA) announced a successful upsized public offering of 12,400,000 American Depositary Shares (ADSs) at $10.50 each, generating gross proceeds of $130.2 million. The offering, which includes an option for underwriters to purchase an additional 1,860,000 ADSs, is set to close on August 15, 2022. Jefferies, Piper Sandler & Co., and Truist Securities are leading the offering, conducted under an effective registration statement filed with the SEC. The funds raised will support Verona’s development in respiratory diseases.
Verona Pharma (Nasdaq: VRNA) announced a proposed underwritten public offering of 10 million American Depositary Shares (ADSs), with each ADS representing eight ordinary shares at a nominal value of £0.05 per share. The offering, managed by Jefferies, Piper Sandler & Co., and Truist Securities, is subject to market conditions. Additionally, the underwriters may purchase up to 1.5 million additional ADSs. This offering is linked to a shelf registration statement previously filed with the SEC.
Verona Pharma reported positive results from its Phase 3 ENHANCE-2 trial for ensifentrine, a treatment for COPD. The trial met its primary and secondary endpoints, showing improved lung function and reduced exacerbation rates. The company also shared financial results, with Q2 2022 cash and equivalents at $111.5 million, down from $132.8 million in Q1. R&D expenses decreased to $15 million, while SG&A expenses fell to $5.5 million. The net loss for the quarter was $17.8 million, an improvement from $22.1 million in Q2 2021. Upcoming data from the ENHANCE-1 trial is anticipated by year-end.
Verona Pharma plc (Nasdaq: VRNA) announced successful Phase 3 ENHANCE-2 trial results for nebulized ensifentrine, demonstrating significant improvements in lung function and a 42% reduction in moderate to severe COPD exacerbations over 24 weeks. The trial met primary and secondary endpoints, showing notable safety and tolerability similar to placebo. Ensifentrine is a first-in-class dual inhibitor targeting COPD treatment. The company plans to submit a New Drug Application to the FDA in early 2023, contingent on ongoing trial results.
Verona Pharma announces the reporting of top-line Phase 3 data from its ENHANCE-2 trial on August 9, 2022. This trial evaluates the efficacy of nebulized ensifentrine for the treatment of COPD. The company will also disclose its financial results for Q2 2022 during an investment community webcast at 8:30 a.m. EDT. Notably, the ENHANCE program includes two studies focused on lung function improvements over 24 weeks, with primary endpoints measuring FEV1. Verona Pharma seeks to address significant unmet needs in respiratory diseases.
Verona Pharma (Nasdaq: VRNA) will announce its second-quarter financial results for the period ending June 30, 2022, on August 15, 2022. A conference call for investors is scheduled for 9:00 a.m. EDT to discuss these results and provide updates on the company’s operations. Verona Pharma is a clinical-stage biopharmaceutical company dedicated to developing therapies for respiratory diseases, specifically through its product candidate, ensifentrine, which is currently in Phase 3 trials for COPD maintenance treatment.
Verona Pharma has completed patient enrollment for its Phase 3 ENHANCE clinical trials, with over 800 subjects in the ENHANCE-1 trial and more than 1,600 across both ENHANCE-1 and ENHANCE-2 trials for ensifentrine, targeting chronic obstructive pulmonary disease (COPD).
Top-line data is anticipated in Q3 2022 and late 2022. The study aims to demonstrate the efficacy of ensifentrine in improving lung function and quality of life for COPD patients, potentially marking a significant advancement in treatment options.
FAQ
What is the current stock price of Verona Pharma plc (VRNA)?
What is the market cap of Verona Pharma plc (VRNA)?
What is Verona Pharma plc?
What is Ensifentrine?
What diseases does Verona Pharma target?
Where is Verona Pharma listed?
Who leads Verona Pharma?
What recent achievements has Verona Pharma made?
What are Verona Pharma’s near-term milestones?
Does Verona Pharma have any partnerships?
What awards has Verona Pharma received?
How can I stay updated on Verona Pharma?
